Table 1.
Demographic and clinical characteristics for patients with E. faecium isolates
| Characteristic (n, %) | Daptomycin susceptible (n=61) | Daptomycin non-susceptible (n=16) | p value |
|---|---|---|---|
| Age, years (median [IQRa]) | 53 (36-64) | 48 (40-62) | 0.80Ŧ |
| Male gender | 37 (61) | 12 (75) | 0.29¶ |
| Cancer type | 0.73¶ | ||
| AML | 37 (61) | 11 (69) | |
| ALL | 14 (23) | 4 (25) | |
| Other leukemia | 10 (16) | 1 (6) | |
| Active chemotherapy | 58 (95) | 16 (100) | 0.37¶ |
| Salvage chemotherapy | 46 (79) | 13 (81) | 0.86¶ |
| ANC < 500 (cells / mm3) | 49 (80) | 15 (94) | 0.20¶ |
| Number of hospital days in previous 90 days (median [IQRa]) | 37 (17-52) | 36 (22-67) | 0.61Ŧ |
| History of stem cell transplant | 22 (36) | 4 (25) | 0.41¶ |
| Positive VREb stool screen within 90 days prior to bacteremia | 38 (62) | 9 (56) | 0.66¶ |
| Select antibiotic use within 90 days prior to bacteremia | |||
| Vancomycin | 21 (34) | 4 (25) | 0.47¶ |
| Linezolid | 57 (93) | 16 (100) | 0.29¶ |
| Levofloxacin | 42 (69) | 13 (81) | 0.33¶ |
| Cefepime | 55 (90) | 12 (75) | 0.11¶ |
| Piperacillin/ tazobactam | 40 (66) | 13 (81) | 0.23¶ |
| Meropenem | 48 (79) | 15 (94) | 0.16¶ |
| Daptomycin usage | |||
| Number of daptomycin days in previous 90 days (median [IQRa]) | 0.0 (0.0-7.0) | 13.0 (4.5-16.0) | <0.01Ŧ |
| Any daptomycin use within 14 days of isolate | 15 (25) | 7 (44) | 0.13¶ |
| Any daptomycin use within 30 days of isolate | 19 (31) | 10 (63) | 0.02¶ |
| Any daptomycin use within 90 days of isolate | 27 (44) | 14 (88) | 0.01¶ |
| ≥ 13 days of daptomycin use within 90 days of isolate | 7 (11) | 9 (60) | 0.01¶∫ |
a
Interquartile range
b
Vancomycin-resistant Enterococcus faecium
Ŧ
Wilcoxon rank-sum test
¶
χ2 test
∫
Relative risk 5.31 (95% CI 2.36–11.96, p <0.01)